NASDAQ:MGTX

Meiragtx Holdings Stock News

etoro logo Buy MGTX
*Your capital is at risk
$12.52
+0.310 (+2.54%)
At Close: Jul 21, 2026
LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,

Why MeiraGTx Holdings Stock Is Down Today

12:43pm, Thursday, 19'th Nov 2020
The company announced the pricing of a public offering of common stock.
LONDON and NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwrit
LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an un
Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retin
LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,
LONDON and NEW YORK,, Nov. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the
12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented 12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented
MGTX share price has failed to recover to pre-COVID-19 levels despite promising developments. MGTX partnership with Janssen on several lead indications.
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
\- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented \- AAV-RPGR to advance into Phase 3 Lumeos clinical trial \- Expands manufacturing cap
LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert
MeiraGTx has been struggling lately, but the selling pressure may be coming to an end soon.
MeiraGTx reports encouraging data for ocular gene therapy. Eli Lilly posts positive update for Mirikizumab.
Every investor in MeiraGTx Holdings plc (NASDAQ:MGTX) should be aware of the most powerful shareholder groups...
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE